The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Recent studies have shown convincingly that vaccines against shingles (Herpes zoster) reduce the risk of dementia.

Residents in public residential aged care services aged 60 and over can now claim a free vaccine for Respiratory Syncytial ...

AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.

Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations face rising infection risks.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are ...